Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jade Biosciences, Inc. (JBIO : NSDQ)

• Company Description    Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $22.21 Daily Weekly Monthly 20 Day Moving Average: 562,391 shares Shares Outstanding: 49.36 (millions) Market Capitalization: $1,096.29 (millions) Beta: 1.52 52 Week High: $28.00 52 Week Low: $6.57 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.90% -16.20% 12 Week 52.54% 41.02% Year To Date 43.94% 39.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 Crescent Street Building 23 Suite 105 - Waltham,MA 02453 USA ph: 781-312-3013 fax: - ir@aerovatetx.com https://jadebiosciences.com

• General Corporate Information    Officers Tom Frohlich - Chief Executive Officer & Director Eric Dobmeier - Chairman Bradford Dahms - Chief Financial Officer and Treasurer Chris Cain - Director Lawrence Klein - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 008064206 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/12/26 Share - Related Items Shares Outstanding: 49.36 Most Recent Split Date: 4.00 (0.03:1) Beta: 1.52 Market Capitalization: $1,096.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.61 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.70 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 81.95% vs. Previous Quarter: -418.18% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -51.34 12/31/25 - -46.55 09/30/25 - -63.80 ROA 03/31/26 - -47.32 12/31/25 - -42.99 09/30/25 - -45.26 Current Ratio 03/31/26 - 14.29 12/31/25 - 21.09 09/30/25 - 9.01 Quick Ratio 03/31/26 - 14.29 12/31/25 - 21.09 09/30/25 - 9.01 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 6.01 12/31/25 - 6.74 09/30/25 - 5.50 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©